Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes    Leukemias    Solid Tumors    Cancer-Prone    Deep Insight    Case Reports    Journals   Portal    Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA
    

Vacuolar H(+)-ATPase in Cancer Cells: Structure and Function

 

Xiaodong Lu1 and Wenxin Qin2

1. School of Medical Science and Laboratory Medicine, Jiangsu University
2. State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine

Address correspondence to:
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital
Shanghai Jiao Tong University School of Medicine, No. 25/Ln 2200 Xie-Tu Road, Shanghai 200032, China
Tel: +86-21-64436581
Fax: +86-21-64432142
E-mail: wqin@shsci.org

 

September 2011

 

 

Vacuolar H+-ATPase (V-ATPase) is a highly evolutionarily conserved enzyme, which is distributed within the plasma membranes and the membranes of some organelles such as endosome, lysosome and secretory vesicle. The mayor function of V-ATPase is to pump protons across the cell membrane to extracellular milieu or across the organelle membrane to intracellular compartments. V-ATPases located in cell surface act as important proton transporters that regulate the cytosolic pH to ~7.0 which is essential for most physiological processes, whereas V-ATPases within intracellular membrane are involved in cellular processes as receptor-mediated endocytosis, membrane trafficking, protein processing or degradation, and nutrients uptake (Nishi et al., 2002; Forgac et al., 2007; Toei et al., 2010; Cruciat et al., 2010). Malfunctioned V-ATPase is closely related to several diseases including tumor. More and more evidences indicate that V-ATPase is an enhancer for carcinogenesis and cancer progression, such as malignant transformation, growth and proliferation, invasion and metastasis, acquirement of multi-drug resistance, etc., which strongly supports that V-ATPase should be an effective target of anticancer strategy (Fais et al., 2007).

The structure of V-ATPases and its expression in tumor cells
The molecular structure of normal V-ATPase of yeast and mammalian cells has been well studied. V-ATPase is a delicate complex which is composed of a cytosolic catalytic domain V1 and an integral domain V0, the former responsible for ATP hydrolysis and the latter providing transmembraneous proton channel (Nishi et al., 2002; Yokoyama et al., 2005; Wang al., 2007). The core of the V1 section is composed of a hexameric arrangement of alternating A and B subunits, which participate in ATP binding and hydrolysis. Other subunits of V1 include three copies of E and G subunits which are the stator, one copy of the regulatory C and H subunits, one copy of subunits D and F which form a central rotor axle. The V0 section includes a ring of proteolipid subunits (c, c' and c") that are adjacent to subunits a and e. Subunits D and F of V1 and subunit a of V0 form the central stalk, whereas the multiple peripheral stalks are composed of subunits C, E, G, H and the N-terminal domain of subunit a. V1 and V0 is connected by both stalks. Several subunits like a, d, e, C, G, H, D and F contain slice variants as to spatial and temporal expression pattern in different cell types (Forgac et al., 2007; Miranda et al., 2010). As for tumor cells, especially those with high metastatic potential, the V-ATPases are usually excessively agitated. The altered structures of V-ATPase of tumor cells may include the increased level of subunit expressions and unique spliced variants of some subunits.
The level of the subunit c expression was found to be related to the metastasis potentials in tumors. One of the studies is the comparison of subunit c expression between normal and pancreatic carcinoma tissues and between invasive and non-invasive pancreatic cancers, which immunohistochemical data showed the notable difference - 92% invasive ductal cancers (42/46) were mild to marked subunit c positive in the cytoplasm, whereas neither non-invasive ductal cancers nor benign cystic neoplasms expressed detectable immunoreactive proteins (Ohta et al., 1996). Subunit c seems to be one of the V-ATPase subunit which significantly influence the proliferation and metastasis of tumor cells. The inhibition of the V-ATPase subunit c via siRNA resulted in the suppression of growth and metastasis of a hepatocellular carcinoma cell line in vitro and in mice model (Lu et al., 2005), which is according to another result of the suppression of subunit c in Hela cell via antisense oligonucleotides (Zhan et al., 2003). But in oral squamous cell carcinoma cells, subunit C1 was the most strongly over-expressed gene at the mRNA level compared to other genes of the V-ATPase complex (Otero-Rey et al., 2008).
Specific spliced variants of subunit have been observed in tumors. A study of expression of subunit a of V-ATPase in breast cancer cell lines displayed the metastasis-specific subunit a isoform expression profile. In highly metastatic breast cancer cell line compared with its lowly metastatic parallel, levels of a3 and a4 were much higher although all the four a isoforms - a1-4 can be detectable. They distribute differently, and especially, a4-containing v-ATPases were located mainly in the plasma membrane of higher metastatic breast cancer cell, seeming to be involved in the formation of the leading surface of the cells due to the combination with F-actin and closely correlated to the potency of invasion. a3-containing V-ATPases were located in intracellular compartment membrane, which regulated the pH of the cytosol and intracellular compartments and also involved in invasion (Hinton et al., 2009). In accordance with this data, the strongly expressed a3 isoform were observed in high-metastatic melanoma cells and in bone metastases (Nishisho et al., 2011). Other tumor-relevant spliced variants are yet to be found.

The roles of the v-ATPase in the growth, proliferation or apoptosis in tumor cells
One of cancer hallmarks is the shift in energy production from oxidative phosphorylation to aerobic glycolysis, ie "Warburg effect", which produces excess intracellular acidosis (Gillies et al., 2008). However, cancer cells usually have neutral to alkaline intracellular pH in the acidized extracellular microenvironment. The V-ATPase is among the four major types of pH regulators (the other three are: Na+/H+ exchangers, bicarbonate transporters, proton/lactate symporters). Much data implies proton pump is essential in tumors and cells seem to render V-ATPases more than any other three transporters to regulate pH in cytosol (Torigoe et al., 2002). The ability to extrude intracellular protons and maintain the cytosol pH is critical for cancer cell survival from a cascade of self-digestion triggered by acidosis.
The inhibition of v-ATPase may induce apoptotic cell death in several human cancer cell lines including pancreatic cancer (Ohta et al., 1998; Hayash et al., 2006), liver cancer (Morimura et al., 2008), gastric cancer (Nakashima et al., 2003), B-cell hybridoma cells (Nishihara et al., 1995; De Milito et al., 2007) and breast cancer (McHenry et al., 2010).The deficiency of V-ATPase will decrease cytosol pH and increased lysosome pH, both of which might influence lysosome function. The apoptosis induced by V-ATPase inhibitors were in either lysosome-mediated or non-lysosome-mediated manner. In the first case, when lysosomal V-ATPase was defected, lysosomal pH and permeability will be increased, resulted in the release of cathepsin D and activation of caspase, with no significant impact on mitochondrial transmembrane potential (Nakashima et al., 2003). In the other case, mitochondria and lysosome might be together involved in V-ATPase-inhibitor-induced apoptosis via capsase pathway or ROS-dependant manner (Ishisaki et al., 1999; De Milito et al., 2007). The inhibition of V-ATPase could also induce apoptosis by suppressing anti-apoptotic Bcl-2 or Bcl-xL and facilitate the caspase-independent apoptotic pathway (Sasazawa et al., 2009). In order to survive from the apoptosis induced by acidosis resulted from glycolysis, tumor cells needs to extrude excessive acid, in which processes V-ATPase plays a crucial role. It is reasonable to postulate that the inhibition of proton extrusion may be more susceptible or vulnerable to cell death of cancer cells than normal cells.
Moreover, the slightly alkalized cytosolic pH favors the growth and proliferation of the cells. Some glycolysis-related enzymes or oncogenes are sensitive the narrow range of pH alteration. Alkalization of cytosol, which mainly regulated by V-ATPase in tumor cells, could activate glycolysis whereas repress oxidative phosphorylation, meanwhile also promote the transcription of oncogenes like HIF-1, akt, myc, ras, etc (Gillies et al., 2008; López-Lázaro, 2008). The cytosol pH of tumor cells was found to be higher than in untransformed controls (Busa et al.,1984; Casey et al., 2010) and increasing cytosol pH was sufficient to confer tumourigenicity to cultured fibroblasts (Perona et al., 1988). On the contrast, p53, the important tumor suppressor could be inactivated in the condition of alkalization (Xiao et al., 2003). It is much likely that the glucose metabolism shift and mutant V-ATPase may be the co-selectors in selecting those "adaptive phenotype", which may take the advantages for survival and proliferation during the initial stage of carcinogenesis.

The functions of the v-ATPase in cellular signals processing
V-ATPase is the important factor that regulates the process of internization and activation of cellular signals. It is mainly due that the V-ATPase is the main contributor of low intracellular vesicles pH, which is essential for various membrane traffic processes. V-ATPase activity influence endocytosis and degradation of molecule-receptor complex, recycling of the released receptor, recruitment of signal molecules, and their proper spatial intracellular distributions (Hurtado-Lorenzo et al., 2006; Marshansky et al., 2008), therefore exerts a profound effect on cell behavior such as growth, proliferation or metastasis via the modulated signals and their pathways. It has been reported that tumor-associated m-TOR (mammalian target of rapamycin) (O'Callaghan et al., 2009), Notch (Fortini and Bilder, 2009; Vaccari et al., 2010) or Wnt (Cruciat et al., 2010; Buechling et al., 2010) could be regulated by V-ATPase.
Early endosomes are important sites for signal molecules internalization and activation in mammalian cells. Studies of the effects of V-ATPases inhibitors on isolated rat hepatocytes and rat sinusoidal endothelial cells suggested that the pH gradient between the endocytic compartments and the cytoplasm was necessary for the receptor-mediated endocytosis (Harada et al., 1996; Harada et al., 1997). Inhibition of V-ATPases can retard recycling of transferrin receptor (Presley et al., 1997), impair the formation of endosomal carrier vesicle (Clague et al., 1994), and inhibit late endosome-lysosome fusion (van Weert et al., 1995). Although the significance of active V-ATPase in signal molecules endocytosis and processing on the behavior of tumor cells is not yet full elucidated for most data was gained from yeast or normal mammalian cells, it could be hypothesized that V-ATPase might regulate some signal pathways via modulating the recycling rate of receptor, which would be responsible for the sensitivity of tumor cells to some signal molecules, ie, the faster rate at which the receptor cycling in a V-ATPase-regulated membrane trafficking, the more efficiently the cells render the receptors, the more signal molecules could be recruited, and the stronger or more lasting response to the stimulation by the signal molecules could be expected.
For example, the activation of Notch, a common hallmark of an increasing number of cancers (Miele et al., 2006; Roy et al., 2007), is involved in V-ATPase-associated endosomal system (Yan et al., 2009; Vaccari et al., 2010). V-ATPase activity is required for Notch signaling. In V-ATPase mutant cells, Notch and its receptors are trapped in an expanded lysosome-like compartment, where they accumulate rather than being degraded and a substantial reduction expression in downstream gene of notch. V-ATPase regulates Notch via: i) endocytosis of Notch, for acidification of earlier endosomal compartments is required in this process and a reduced rate of Notch endocytosis was found in V-ATPase mutant cells ii) endosomal cleavage patterns of the protease that degrade the Notch in the accordingly forms, each of which process exerting its own activating potency (Vaccari et al., 2010) iii) regulating endosome-lysosome fusion and Notch intracellular re-distribution or the targeting to cell surface.
The V-ATPase-associated signal molecules processing itself may also be regulated by endosomal protein, for example, HRG-1(heme-regulated genes), a downstream gene of IGF-I (insulin-like growth factor) and having an interaction with subunit c. HRG-1 could promote endosomal acidification and receptor trafficking, enhance the proliferative and invasive phenotype of cancer cells. It was implied that the increased active V-ATPase by HRG-1 not only regulate the endocytosis and degradation of receptors that promote signaling for survival, growth, and migration of cancer tumor, but also facilitate micronutrient uptake necessary for tumor cellular metabolism (O'Callaghan et al., 2009).

The contributions of the V-ATPase in cancer metastasis
Invasion and metastasis is the relatively late event of development of malignant cells, which is the continuous process of breaking through the basement membrane, degrading extracellular matrix, angiogenesis, invading vascular system and redistributing in the distinct host sites. The activation of the proteases which break down extracellular matrix is required during the procedure. The invasive phenotype is closely related to its highly active V-ATPase. It has been reported that the improper activated V-ATPases correlates with an invasive phenotype of several types of tumors, including breast cancer (Sennoune et al., 2004; Hinton et al., 2009), pancreatic cancer (Chung et al., 2011) and melanoma (Nishisho et al., 2011). The tumor metastasis can be suppressed in vitro or in animal model by the inhibition of V-ATPase inhibitors or siRNA (Lu et al., 2005; Hinton et al., 2009; Supino et al., 2008). Subunit a isoform and c seem to be important factors in regulating the metastasis of cancer.
The main mechanisms by which overly active V-ATPases enhance the tumor invasion and metastasis may be that the extracellular milieu is acidized and it is suitable for optimal pH of proteases that degenerate extracellular matrix (ECM). The plasma membrane V-ATPases is responsible for pumping cytosol protons to the extracellular space resulting in a low extracelluar pH, which is required for the activation of several types of proteases including cathepsins, metalloproteases, and gelatinases. V-ATPase may influence the expression of proteases directly independent of the whole enzyme V-ATPase function. For example, transfectants which over express V-ATPase subunit c at the mRNA level showed an enhance invasiveness in vitro with a concomitant increases in secretion of matrix metalloproteinase-2 (Kubota et al., 2000). V-ATPase may also regulate metastasis by enhancing proteases activation. Cathepsin is an example, which is secreted by several types of tumor cells and related to invasion. Once the extracellular cathepsin is activated, it can both degrade extracellular matrix proteins and activate other secreted proteases involved in invasion, such as matrix metalloprotease (Joyce et al., 2004; Gocheva et al., 2007) and gelatinases (Martínez-Zaguilá et al., 1996). The plasma membrane V-ATPase appeared to be recruited at the proceeding edge of the cancer cell by the interaction with F-actin so as to give rise an acidic microenvironment by the edge (Hinton et al., 2009). Moreover, intracellular V-ATPases, the major contributor of acidity of intracellular compartment and membrane trafficking regulator, also facilitate in the invasion and metastasis, which is due to possible modulating proteolytic activation of cathepsins or matrix metalloproteases within lysosomes or secretory vesicles and targeting the proteases-containing secretory vesicles to the cell surface to be extracytosed (Hinton et al., 2009). The accumulation of acidity, concentration of plasma membrane V-ATPase and activated protease crown the proceeding surface of a metastatic cell, conferring the tumor cell a "cutting edge".
Mobility is crucial for spread of tumor cells to the distant sites. NiK-12192, one of V-ATPase inhibitor was shown able to reduce the migration/invasion of human lung cancer cells in vitro and significantly reduce the number of spontaneous metastases in the lung of nude mice implanted with a human lung carcinoma. After the treatment of NiK-12192, the lung cancer cells in vitro showed that actin fibers were broken, spots of aggregation were evident and no pseudopodia and regular structure for actin filaments could be seen, comparing to the control cells with long and regular fibers of tubulin in the cell cytoplasm and filaments of actin forming pseudopodia. NiK-12192-treated cells also demonstrate a reduction in the experiment of wound healing assay due to the retard of migration (Supino et al., 2008). V-ATPase subunit B and C appear to contain the binding sites to the actin cytoskeleton (Vitavska et al., 2003; Vitavska et al., 2005; Zuo et al., 2006). The interactions between V-ATPase and cytoskeleton implicate their involvement and regulation of cell mobility and membrane trafficking (Sun-Wada et al., 2009).
Angiogenesis, a consequence of the mutual interaction between cancer cells and the stoma cells of extracellular microenvironments, is another important step during metastasis, during which process, endothelial cells is mainly involved. It was documented that V- ATPases play a crucial role in growth and phenotypic modulation of myofibroblasts that contribute to neointimal formation in cultured human saphenous vein (Otani et al., 2000) The microvascular endothelial cells in tumor tissue also incline to render plasma membrane V-ATPase to cope with the acidic extracellular environment. The ability of migration of endothelial cell toward the adjacent tissue is required during angiogenesis, in which process V-ATPase plays a role, shown in the result that the penetration of basement membrane of endothelial cell was suppressed by bafilomycin treatment (Rojas et al., 2006).

The relations of V-ATPase and drug resistance in cancer
Acquired multidrug resistance (MDR) can limit therapeutic potential and one of the reasons of relapse. It is well known that MDR is correlate to the evolutionarily conserved family of the ATP binding cassette (ABC) proteins pg, yet it is documented that V-ATPase plays a role in MDR in a pg-independent manner, and the inhibition of V-ATPase could not only suppress tumor cells directly, but also sensitize the tumor cells to the chemical therapy (De Milito et al., 2005). It was documented that proton pump inhibitor (PPI) pretreatment sensitized tumor cell lines to the effects of cisplatin, 5-fluorouracil, and vinblastine significantly. PPI treatment will increases both extracellular pH and the pH of lysosomal organelles, which induced a marked increase in the cytoplasmic retention of the cytotoxic drugs, with clear targeting to the nucleus in the case of doxorubicin. In vivo experiments, oral pretreatment with omeprazole was able to induce sensitivity of human solid tumors to cisplatin (Lucian et al., 2004).
V-ATPase renders several mechanisms of multidrug resistance including: neutralized drug extracellularly or intracellularly, decreased drug internalization, altered DNA repair and inhibition of apoptosis. The pH of the tumor microenvironment may influence the uptake of anticancer drugs. Molecules diffuse passively across the cell membrane most efficiently in the uncharged form. Because the extracellular pH in tumors is low and the intracellular pH of tumor cells is neutral to alkaline, weakly basic drugs that have an acid dissociation constant of 7.5-9.5, such as doxorubicin, mitoxantrone, vincristine, and vinblastine, are protonated and display decreased cellular uptake (Raghunand et al., 1999; Gerweck et al., 2006; McCarty and Whitaker, 2010). The data in vitro or in animal models indicates that extracellular alkalinization leads to substantial improvement in the therapeutic effectiveness of antitumor drugs via enhanced the cellular drug uptake and cytotoxicity (Gerweck et al., 2006; Trédan et al., 2007).The reduced intracellular accumulation of anticancer drugs may also be due that V-ATPase has a role as cooperating factor of ATP-dependent membrane proteins that function as drug efflux pumps (Raghunand et al., 1999). Interestingly, the levels of V-ATPase subunit expressions can be up-regulated by anticancer drug. The treatment of cisplatin on human epidermoid cancer KB cells increased the protein levels of the majority of the subunits such as c, c", D, a, A, C and E, which indicates it may stimulate the expression of the V-ATPase complex as a whole. It is suggested that the V-ATPase expression may be a defensive response to the anticancer drug (Murakami et al., 2001; Torigoe et al., 2002). Still, there are also some controversial results on the relationship between the cationic drugs uptake and V-ATPase - the inhibition of V-ATPase decreased the uptake of the cationic drugs (Morissette et al., 2009; Marceau et al., 2009), which might be explained that the influence of V-ATPase on the drug uptake may also be depend upon the characteristics of the drugs and its relation to membrane trafficking.
That the defects of V-ATPase increase the sensitivity to drugs may be partly due to the decreased cytosolic pH, which were observed in the influence of cisplatin on the V-ATPase mutant yeast Saccharomyces cerevisiae (Liao et al., 2006) or increased toxicity of combined treatment of V-ATPase inhibition and anticancer drug on lung cancer cell, breast cancer or liver cancer cell lines (Wong et al., 2005; Farina et al., 2006; You et al., 2009). At low cytosolic pH, sensitivity to DNA damaging drugs or UV irradiation in V-ATPase mutants may be associated with altered DNA conformation or defective DNA damage repair mechanisms, rendering DNA more prone to damage (Robinson et al., 1992; Petrangolini et al., 2006; Liao et al., 2006).

The roles of V-ATPase in cancer cells. 1) Protons produced by glycolysis are pumped by plasma membrane V-ATPase (green circle: V0; blue circle: V1) which prevents the cell from acidosis-induced apoptosis and the slightly basic of cytosolic pH enhanced cell growth and proliferation; 2) Acidification of secretary vesicle, which is maintained by intracellular V-ATPase, is essential for protease secretion and activation (orange bars: active form; orange-red bars: inactive forms of protease). The interaction between V-ATPase and actin (green wave line) may contribute the recruitment of V-ATPase on plasma membrane. The accumulation of V-ATPase on the plasma membrane, the extracellular acidic-microenvironment and activated-protease appear to crown the tumor cell, conferring it a "cutting edge" at the proceeding surface which facilitates invasion and metastasis. Moreover, in acidic microenvironment, angiogenesis is enhanced; 3) V-ATPases might regulate signal pathway via controlling international of signal molecules (red circle), releasing and recycling the receptors, and processing signal molecules. Therefore, V-ATPases may exert effects on cell behavior via signal pathway; 4) V-ATPases contributes to acquirement of resistance of anticancer drug (green square) supported by the data that inhibition of V-ATPase sensitize the tumor cells to chemical therapy, which is partly due to the increased influx of anticancer drug when in a basic extracellular condition.

Conclusions
According to the roles V-ATPase in tumor cells, we conclude that alteration of V-ATPase is much likely the necessary initial step of transformation of the malignant cells and the malfunctional V-ATPase acts as a continual enhancer of carcinogenesis and tumor progression. Tumor cells take the advantages of disfunctioned plasma and intracellular V-ATPase in these aspects: enhanced proliferation and growth, evading apoptosis, facilitating metastasis and angiogenesis, and acquirement of the drug resistance. V-ATPase will be a prospective candidate for cancer diagnosis and treatment.

Bibliography

Metabolic regulation via intracellular pH.
Busa WB, Nuccitelli R.
Am J Physiol. 1984 Apr;246(4 Pt 2):R409-38. (REVIEW)
PMID 6326601
 
Increased pH and tumorigenicity of fibroblasts expressing a yeast proton pump.
Perona R, Serrano R.
Nature. 1988 Aug 4;334(6181):438-40.
PMID 2900469
 
Unusual DNA conformation at low pH revealed by NMR: parallel-stranded DNA duplex with homo base pairs.
Robinson H, van der Marel GA, van Boom JH, Wang AH.
Biochemistry. 1992 Nov 3;31(43):10510-7.
PMID 1420168
 
Vacuolar ATPase activity is required for endosomal carrier vesicle formation.
Clague MJ, Urbe S, Aniento F, Gruenberg J.
J Biol Chem. 1994 Jan 7;269(1):21-4.
PMID 8276796
 
Specific inhibitors of vacuolar type H(+)-ATPases induce apoptotic cell death.
Nishihara T, Akifusa S, Koseki T, Kato S, Muro M, Hanada N.
Biochem Biophys Res Commun. 1995 Jul 6;212(1):255-62.
PMID 7612014
 
Transport from late endosomes to lysosomes, but not sorting of integral membrane proteins in endosomes, depends on the vacuolar proton pump.
van Weert AW, Dunn KW, Gueze HJ, Maxfield FR, Stoorvogel W.
J Cell Biol. 1995 Aug;130(4):821-34.
PMID 7642700
 
Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPases, inhibits the receptor-mediated endocytosis of asialoglycoproteins in isolated rat hepatocytes.
Harada M, Sakisaka S, Yoshitake M, Kin M, Ohishi M, Shakado S, Mimura Y, Noguchi K, Sata M, Tanikawa K.
J Hepatol. 1996 May;24(5):594-603.
PMID 8773916
 
Acidic pH enhances the invasive behavior of human melanoma cells.
Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ.
Clin Exp Metastasis. 1996 Mar;14(2):176-86.
PMID 8605731
 
Expression of 16 kDa proteolipid of vacuolar-type H(+)-ATPase in human pancreatic cancer.
Ohta T, Numata M, Yagishita H, Futagami F, Tsukioka Y, Kitagawa H, Kayahara M, Nagakawa T, Miyazaki I, Yamamoto M, Iseki S, Ohkuma S.
Br J Cancer. 1996 Jun;73(12):1511-7.
PMID 8664121
 
Bafilomycin A1, a specific inhibitor of V-type H+-ATPases, inhibits the acidification of endocytic structures and inhibits horseradish peroxidase uptake in isolated rat sinusoidal endothelial cells.
Harada M, Shakado S, Sakisaka S, Tamaki S, Ohishi M, Sasatomi K, Koga H, Sata M, Tanikawa K.
Liver. 1997 Oct;17(5):244-50.
PMID 9387916
 
Bafilomycin A1 treatment retards transferrin receptor recycling more than bulk membrane recycling.
Presley JF, Mayor S, McGraw TE, Dunn KW, Maxfield FR.
J Biol Chem. 1997 May 23;272(21):13929-36.
PMID 9153255
 
Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan-1.
Ohta T, Arakawa H, Futagami F, Fushida S, Kitagawa H, Kayahara M, Nagakawa T, Miwa K, Kurashima K, Numata M, Kitamura Y, Terada T, Ohkuma S.
J Pathol. 1998 Jul;185(3):324-30.
PMID 9771488
 
Caspase-3 activation during the process of apoptosis induced by a vacuolar type H(+)-ATPase inhibitor.
Ishisaki A, Hashimoto S, Amagasa T, Nishihara T.
Biol Cell. 1999 Sep;91(7):507-13.
PMID 10572626
 
Enhancement of chemotherapy by manipulation of tumour pH.
Raghunand N, He X, van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-Murrieta G, Roe D, Bhujwalla ZM, Gillies RJ.
Br J Cancer. 1999 Jun;80(7):1005-11.
PMID 10362108
 
Overexpression of vacuolar ATPase 16-kDa subunit in 10T1/2 fibroblasts enhances invasion with concomitant induction of matrix metalloproteinase-2.
Kubota S, Seyama Y.
Biochem Biophys Res Commun. 2000 Nov 19;278(2):390-4.
PMID 11097847
 
Vacuolar H(+)-ATPase plays a crucial role in growth and phenotypic modulation of myofibroblasts in cultured human saphenous vein.
Otani H, Yamamura T, Nakao Y, Hattori R, Fujii H, Ninomiya H, Kido M, Kawaguchi H, Osako M, Imamura H, Ohta T, Ohkuma S.
Circulation. 2000 Nov 7;102(19 Suppl 3):III269-74.
PMID 11082400
 
Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance.
Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S, Nakagawa M, Izumi H, Nakamura T, Matsuo K, Yamada Y, Kohno K.
Int J Cancer. 2001 Sep;93(6):869-74.
PMID 11519050
 
The vacuolar (H+)-ATPases--nature's most versatile proton pumps.
Nishi T, Forgac M.
Nat Rev Mol Cell Biol. 2002 Feb;3(2):94-103. (REVIEW)
PMID 11836511
 
Vacuolar H(+)-ATPase: functional mechanisms and potential as a target for cancer chemotherapy.
Torigoe T, Izumi H, Ise T, Murakami T, Uramoto H, Ishiguchi H, Yoshida Y, Tanabe M, Nomoto M, Kohno K.
Anticancer Drugs. 2002 Mar;13(3):237-43. (REVIEW)
PMID 11984067
 
Enhanced expression of the human vacuolar H+-ATPase c subunit gene (ATP6L) in response to anticancer agents.
Torigoe T, Izumi H, Ishiguchi H, Uramoto H, Murakami T, Ise T, Yoshida Y, Tanabe M, Nomoto M, Itoh H, Kohno K.
J Biol Chem. 2002 Sep 27;277(39):36534-43. Epub 2002 Jul 19.
PMID 12133827
 
Vacuolar H+-ATPase inhibitor induces apoptosis via lysosomal dysfunction in the human gastric cancer cell line MKN-1.
Nakashima S, Hiraku Y, Tada-Oikawa S, Hishita T, Gabazza EC, Tamaki S, Imoto I, Adachi Y, Kawanishi S.
J Biochem. 2003 Sep;134(3):359-64.
PMID 14561721
 
A novel role for subunit C in mediating binding of the H+-V-ATPase to the actin cytoskeleton.
Vitavska O, Wieczorek H, Merzendorfer H.
J Biol Chem. 2003 May 16;278(20):18499-505. Epub 2003 Feb 25.
PMID 12606563
 
Acidic pH induces topoisomerase II-mediated DNA damage.
Xiao H, Li TK, Yang JM, Liu LF.
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5205-10. Epub 2003 Apr 11.
PMID 12692309
 
Different roles of proteolipids and 70-kDa subunits of V-ATPase in growth and death of cultured human cells.
Zhan H, Yokoyama K, Otani H, Tanigaki K, Shirota N, Takano S, Ohkuma S.
Genes Cells. 2003 Jun;8(6):501-13.
PMID 12786941
 
Multiple roles for cysteine cathepsins in cancer.
Joyce JA, Hanahan D.
Cell Cycle. 2004 Dec;3(12):1516-619. Epub 2004 Dec 6. (REVIEW)
PMID 15539953
 
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, Federici C, Iessi E, Parmiani G, Arancia G, Belardelli F, Fais S.
J Natl Cancer Inst. 2004 Nov 17;96(22):1702-13.
PMID 15547183
 
Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity.
Sennoune SR, Bakunts K, Martinez GM, Chua-Tuan JL, Kebir Y, Attaya MN, Martinez-Zaguilan R.
Am J Physiol Cell Physiol. 2004 Jun;286(6):C1443-52. Epub 2004 Feb 4.
PMID 14761893
 
Tumor acidity, chemoresistance and proton pump inhibitors.
De Milito A, Fais S.
Future Oncol. 2005 Dec;1(6):779-86. (REVIEW)
PMID 16556057
 
The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump.
Lu X, Qin W, Li J, Tan N, Pan D, Zhang H, Xie L, Yao G, Shu H, Yao M, Wan D, Gu J, Yang S.
Cancer Res. 2005 Aug 1;65(15):6843-9.
PMID 16061667
 
The V-ATPase subunit C binds to polymeric F-actin as well as to monomeric G-actin and induces cross-linking of actin filaments.
Vitavska O, Merzendorfer H, Wieczorek H.
J Biol Chem. 2005 Jan 14;280(2):1070-6. Epub 2004 Nov 3.
PMID 15525650
 
Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells.
Wong P, Lee C, Tannock IF.
Clin Cancer Res. 2005 May 1;11(9):3553-7.
PMID 15867259
 
Rotation, structure, and classification of prokaryotic V-ATPase.
Yokoyama K, Imamura H.
J Bioenerg Biomembr. 2005 Dec;37(6):405-10. (REVIEW)
PMID 16691473
 
Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics.
Gerweck LE, Vijayappa S, Kozin S.
Mol Cancer Ther. 2006 May;5(5):1275-9.
PMID 16731760
 
Effects of bafilomycin A1, a vacuolar type H+ ATPase inhibitor, on the thermosensitivity of a human pancreatic cancer cell line.
Hayashi Y, Katayama K, Togawa T, Kimura T, Yamaguchi A.
Int J Hyperthermia. 2006 Jun;22(4):275-85.
PMID 16754349
 
V-ATPase interacts with ARNO and Arf6 in early endosomes and regulates the protein degradative pathway.
Hurtado-Lorenzo A, Skinner M, El Annan J, Futai M, Sun-Wada GH, Bourgoin S, Casanova J, Wildeman A, Bechoua S, Ausiello DA, Brown D, Marshansky V.
Nat Cell Biol. 2006 Feb;8(2):124-36. Epub 2006 Jan 15.
PMID 16415858
 
Notch signaling in cancer.
Miele L, Golde T, Osborne B.
Curr Mol Med. 2006 Dec;6(8):905-18. (REVIEW)
PMID 17168741
 
Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins.
Petrangolini G, Supino R, Pratesi G, Dal Bo L, Tortoreto M, Croce AC, Misiano P, Belfiore P, Farina C, Zunino F.
J Pharmacol Exp Ther. 2006 Sep;318(3):939-46. Epub 2006 May 19.
PMID 16714402
 
Vacuolar-type H+-ATPases at the plasma membrane regulate pH and cell migration in microvascular endothelial cells.
Rojas JD, Sennoune SR, Maiti D, Bakunts K, Reuveni M, Sanka SC, Martinez GM, Seftor EA, Meininger CJ, Wu G, Wesson DE, Hendrix MJ, Martinez-Zaguilan R.
Am J Physiol Heart Circ Physiol. 2006 Sep;291(3):H1147-57. Epub 2006 May 5.
PMID 16679513
 
Actin binding activity of subunit B of vacuolar H+-ATPase is involved in its targeting to ruffled membranes of osteoclasts.
Zuo J, Jiang J, Chen SH, Vergara S, Gong Y, Xue J, Huang H, Kaku M, Holliday LS.
J Bone Miner Res. 2006 May;21(5):714-21.
PMID 16734386
 
Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species.
De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino ML, Federici C, Perdicchio M, Matarrese P, Lugini L, Nilsson A, Fais S.
Cancer Res. 2007 Jun 1;67(11):5408-17.
PMID 17545622
 
Targeting vacuolar H+-ATPases as a new strategy against cancer.
Fais S, De Milito A, You H, Qin W.
Cancer Res. 2007 Nov 15;67(22):10627-30. (REVIEW)
PMID 18006801
 
Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology.
Forgac M.
Nat Rev Mol Cell Biol. 2007 Nov;8(11):917-29. (REVIEW)
PMID 17912264
 
Cysteine cathepsins and the cutting edge of cancer invasion.
Gocheva V, Joyce JA.
Cell Cycle. 2007 Jan 1;6(1):60-4. Epub 2007 Jan 6. (REVIEW)
PMID 17245112
 
Genomic screening in vivo reveals the role played by vacuolar H+ ATPase and cytosolic acidification in sensitivity to DNA-damaging agents such as cisplatin.
Liao C, Hu B, Arno MJ, Panaretou B.
Mol Pharmacol. 2007 Feb;71(2):416-25. Epub 2006 Nov 8.
PMID 17093137
 
The multifaceted role of Notch in cancer.
Roy M, Pear WS, Aster JC.
Curr Opin Genet Dev. 2007 Feb;17(1):52-9. Epub 2006 Dec 18. (REVIEW)
PMID 17178457
 
Drug resistance and the solid tumor microenvironment.
Tredan O, Galmarini CM, Patel K, Tannock IF.
J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54. Epub 2007 Sep 25. (REVIEW)
PMID 17895480
 
Arrangement of subunits in the proteolipid ring of the V-ATPase.
Wang Y, Cipriano DJ, Forgac M.
J Biol Chem. 2007 Nov 23;282(47):34058-65. Epub 2007 Sep 25.
PMID 17897940
 
Intracellular pH regulation in oral squamous cell carcinoma is mediated by increased V-ATPase activity via over-expression of the ATP6V1C1 gene.
Otero-Rey EM, Somoza-Martin M, Barros-Angueira F, Garcia-Garcia A.
Oral Oncol. 2008 Feb;44(2):193-9. Epub 2007 Apr 27.
PMID 17467328
 
Causes and consequences of increased glucose metabolism of cancers.
Gillies RJ, Robey I, Gatenby RA.
J Nucl Med. 2008 Jun;49 Suppl 2:24S-42S. (REVIEW)
PMID 18523064
 
The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen?
Lopez-Lazaro M.
Anticancer Agents Med Chem. 2008 Apr;8(3):305-12. (REVIEW)
PMID 18393789
 
The V-type H+-ATPase in vesicular trafficking: targeting, regulation and function.
Marshansky V, Futai M.
Curr Opin Cell Biol. 2008 Aug;20(4):415-26. Epub 2008 May 27. (REVIEW)
PMID 18511251
 
The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma.
Morimura T, Fujita K, Akita M, Nagashima M, Satomi A.
Pediatr Surg Int. 2008 Oct;24(10):1087-94.
PMID 18712525
 
Antimetastatic effect of a small-molecule vacuolar H+-ATPase inhibitor in in vitro and in vivo preclinical studies.
Supino R, Petrangolini G, Pratesi G, Tortoreto M, Favini E, Bo LD, Casalini P, Radaelli E, Croce AC, Bottiroli G, Misiano P, Farina C, Zunino F.
J Pharmacol Exp Ther. 2008 Jan;324(1):15-22. Epub 2007 Oct 1.
PMID 17909082
 
Endocytic regulation of Notch signaling.
Fortini ME, Bilder D.
Curr Opin Genet Dev. 2009 Aug;19(4):323-8. Epub 2009 May 15. (REVIEW)
PMID 19447603
 
Function of a subunit isoforms of the V-ATPase in pH homeostasis and in vitro invasion of MDA-MB231 human breast cancer cells.
Hinton A, Sennoune SR, Bond S, Fang M, Reuveni M, Sahagian GG, Jay D, Martinez-Zaguilan R, Forgac M.
J Biol Chem. 2009 Jun 12;284(24):16400-8. Epub 2009 Apr 14.
PMID 19366680
 
Vacuolar ATPase-mediated cellular concentration and retention of quinacrine: a model for the distribution of lipophilic cationic drugs to autophagic vacuoles.
Marceau F, Bawolak MT, Bouthillier J, Morissette G.
Drug Metab Dispos. 2009 Dec;37(12):2271-4. Epub 2009 Sep 22.
PMID 19773536
 
Intracellular sequestration of amiodarone: role of vacuolar ATPase and macroautophagic transition of the resulting vacuolar cytopathology.
Morissette G, Ammoury A, Rusu D, Marguery MC, Lodge R, Poubelle PE, Marceau F.
Br J Pharmacol. 2009 Aug;157(8):1531-40. Epub 2009 Jul 7.
PMID 19594752
 
Vacuolar H+-ATPase inhibitors overcome Bcl-xL-mediated chemoresistance through restoration of a caspase-independent apoptotic pathway.
Sasazawa Y, Futamura Y, Tashiro E, Imoto M.
Cancer Sci. 2009 Aug;100(8):1460-7. Epub 2009 May 13.
PMID 19459857
 
Direct recruitment of H+-ATPase from lysosomes for phagosomal acidification.
Sun-Wada GH, Tabata H, Kawamura N, Aoyama M, Wada Y.
J Cell Sci. 2009 Jul 15;122(Pt 14):2504-13. Epub 2009 Jun 23.
PMID 19549681
 
The vacuolar proton pump, V-ATPase, is required for notch signaling and endosomal trafficking in Drosophila.
Yan Y, Denef N, Schupbach T.
Dev Cell. 2009 Sep;17(3):387-402.
PMID 19758563
 
Small interfering RNA targeting the subunit ATP6L of proton pump V-ATPase overcomes chemoresistance of breast cancer cells.
You H, Jin J, Shu H, Yu B, De Milito A, Lozupone F, Deng Y, Tang N, Yao G, Fais S, Gu J, Qin W.
Cancer Lett. 2009 Jul 18;280(1):110-9. Epub 2009 Mar 18.
PMID 19299075
 
Wnt/Frizzled signaling requires dPRR, the Drosophila homolog of the prorenin receptor.
Buechling T, Bartscherer K, Ohkawara B, Chaudhary V, Spirohn K, Niehrs C, Boutros M.
Curr Biol. 2010 Jul 27;20(14):1263-8. Epub 2010 Jun 24.
PMID 20579883
 
Sensors and regulators of intracellular pH.
Casey JR, Grinstein S, Orlowski J.
Nat Rev Mol Cell Biol. 2010 Jan;11(1):50-61. Epub 2009 Dec 9. (REVIEW)
PMID 19997129
 
Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling.
Cruciat CM, Ohkawara B, Acebron SP, Karaulanov E, Reinhard C, Ingelfinger D, Boutros M, Niehrs C.
Science. 2010 Jan 22;327(5964):459-63.
PMID 20093472
 
Manipulating tumor acidification as a cancer treatment strategy.
McCarty MF, Whitaker J.
Altern Med Rev. 2010 Sep;15(3):264-72. (REVIEW)
PMID 21155627
 
Iejimalides A and B inhibit lysosomal vacuolar H+-ATPase (V-ATPase) activity and induce S-phase arrest and apoptosis in MCF-7 cells.
McHenry P, Wang WL, Devitt E, Kluesner N, Davisson VJ, McKee E, Schweitzer D, Helquist P, Tenniswood M.
J Cell Biochem. 2010 Mar 1;109(4):634-42.
PMID 20039309
 
An extended nomenclature for mammalian V-ATPase subunit genes and splice variants.
Miranda KC, Karet FE, Brown D.
PLoS One. 2010 Mar 10;5(3):e9531.
PMID 20224822
 
Heme-binding protein HRG-1 is induced by insulin-like growth factor I and associates with the vacuolar H+-ATPase to control endosomal pH and receptor trafficking.
O'Callaghan KM, Ayllon V, O'Keeffe J, Wang Y, Cox OT, Loughran G, Forgac M, O'Connor R.
J Biol Chem. 2010 Jan 1;285(1):381-91. Epub 2009 Oct 29.
PMID 19875448
 
Regulation and isoform function of the V-ATPases.
Toei M, Saum R, Forgac M.
Biochemistry. 2010 Jun 15;49(23):4715-23. (REVIEW)
PMID 20450191
 
The vacuolar ATPase is required for physiological as well as pathological activation of the Notch receptor.
Vaccari T, Duchi S, Cortese K, Tacchetti C, Bilder D.
Development. 2010 Jun;137(11):1825-32.
PMID 20460366
 
The vacuolar-ATPase modulates matrix metalloproteinase isoforms in human pancreatic cancer.
Chung C, Mader CC, Schmitz JC, Atladottir J, Fitchev P, Cornwell ML, Koleske AJ, Crawford SE, Gorelick F.
Lab Invest. 2011 May;91(5):732-43. Epub 2011 Feb 21.
PMID 21339745
 
The a3 isoform vacuolar type H(+)-ATPase promotes distant metastasis in the mouse B16 melanoma cells.
Nishisho T, Hata K, Nakanishi M, Morita Y, Sun-Wada GH, Wada Y, Yasui N, Yoneda T.
Mol Cancer Res. 2011 Jul;9(7):845-55. Epub 2011 Jun 13.
PMID 21669964
 
Written2011-09Xiaodong Lu, Wenxin Qin
of Medical Science, Laboratory Medicine, Jiangsu University, China (XL); State Key Laboratory of Oncogenes, Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China (WQ)

Citation

This paper should be referenced as such :
Lu, X ; Qin, W
Vacuolar H(+)-ATPase in Cancer Cells: Structure, Function
Atlas Genet Cytogenet Oncol Haematol. 2012;16(3):252-259.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Deep/V-ATPaseInCancerID20104.htm

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Jun 30 11:26:16 CEST 2017


Home   Genes    Leukemias    Solid Tumors    Cancer-Prone    Deep Insight    Case Reports    Journals   Portal    Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.